UK markets open in 3 hours 58 minutes
  • NIKKEI 225

    26,685.71
    +7.91 (+0.03%)
     
  • HANG SENG

    20,006.88
    -164.39 (-0.81%)
     
  • CRUDE OIL

    110.94
    +0.61 (+0.55%)
     
  • GOLD FUTURES

    1,849.20
    +2.90 (+0.16%)
     
  • DOW

    32,120.28
    +191.66 (+0.60%)
     
  • BTC-GBP

    23,670.99
    -357.76 (-1.49%)
     
  • CMC Crypto 200

    661.74
    -9.26 (-1.38%)
     
  • ^IXIC

    11,434.74
    +170.29 (+1.51%)
     
  • ^FTAS

    4,147.08
    +20.29 (+0.49%)
     

Evolva signs distribution agreement for its Veri-teTM Resveratrol for dietary supplements in Brazil

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Evolva Holding SA / Key word(s): Agreement/Development of Sales

12-May-2022 / 07:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Ad Hoc Announcement (PDF)

PRESS RELEASE | AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR

  • Distribution agreement signed with Tovani Benzaquen Ingredients to jointly develop the Brazilian business

  • Minimum revenues of CHF 1.5 million expected from the partnership

Reinach, May 12, 2022 Evolva (SIX:EVE), a pioneer in the field of natural molecules and industrial biotech, today announced the signing of a distribution agreement with Tovani Benzaquen Ingredients (“Tovani”; tovani.com.br) to jointly develop the Brazilian business for Veri-teTM Resveratrol.

The agreement provides Evolva with access to an attractive segment of the Brazilian market for dietary supplements. Revenues are expected to exceed a minimum of CHF 1.5 million over the next 2.5 years from this partnership. Evolva’s Veri-teTM Resveratrol is approved for sale in dietary supplements in Brazil by the Brazilian regulator ANVISA (Agência Nacional de Vigilância Sanitária) and the signing of this distribution agreement with Tovani now allows Evolva to capitalize on the market potential.

Elzo Benzaquen, CEO of Tovani, comments: “As a leading player in this relevant market segment for Veri-teTM Resveratrol in Brazil, Tovani is keen to develop this business together with our partner Evolva. The trend towards healthier and more conscious lifestyles strongly supports functional ingredients based on nature such as Evolva’s Resveratrol. We are excited to offer the differentiating benefits of Veri-teTM Resveratrol, which have been demonstrated in clinical trials such as the reputed RESHAW Study, to our customers.”

Christian Wichert, CEO of Evolva, adds: “The distribution agreement with Tovani marks an important milestone for our company. It opens-up the Brazilian market for our Veri-teTM Resveratrol offering. Veri-teTM Resveratrol is today the main pillar of our Health Ingredients business and a key contributor to our initiatives to significantly boost future growth. Today’s agreement further underlines the positive market momentum for Evolva.”

About Veri-teTM Resveratrol
Resveratrol is a polyphenolic compound that occurs naturally in plant sources such as grapes, peanuts, cranberries and other berries, albeit at low concentrations. Evolva’s Veri-teTM Resveratrol is a nature-based high-purity ingredient, made via fermentation, which ensures a stable, traceable and reliable supply. The ingredient is offered in different formats such as a cold-water dispersible or an oil and water soluble resveratrol and is sold to dietary supplements’, functional beverages, cosmetics’, pharma applications and animal health markets.

About Evolva
Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. The company has leading businesses in Flavors and Fragrances, Health Ingredients and Health Protection. Evolva’s employees, half of which are women, are dedicated to make the best products that can contribute to health, wellness and sustainability. Find out more at evolva.com and connect with us on LinkedIn.

For Evolva multimedia content, please visit: evolva.com/multimedia-library.

Important date(s)
August 25, 2022 Half-year 2022 Report

Contact
Thomas Schneckenburger, PhD, CFA
Head of Investor and Corporate Relations
+41 61 485 2003
+41 79 407 9952

thomass@evolva.com

Disclaimer
This announcement is not an offer of securities into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, in the United States, except pursuant to an exemption from, or transaction not subject to, the registration requirements of the Securities Act. No public offering of securities is being made in the United States. Further, the securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan or under the applicable securities laws of any other jurisdiction where to do so might constitute a violation of such laws.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.


End of ad hoc announcement

Language:

English

Company:

Evolva Holding SA

Duggingerstrasse 23

4153 Reinach

Switzerland

Phone:

+41 61 485 20 00

Internet:

www.evolva.com

ISIN:

CH0021218067

Valor:

2121806

Listed:

SIX Swiss Exchange

EQS News ID:

1350295


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting